Zion Market Research

General Anxiety Disorder Market to Exceed $3,775 Mn by 2020

U.S. general anxiety disorder market expected to reach USD 3,775 million by end of 2020, growing at a CAGR of 2.4% during 2015 and 2020.


Sarasota, FL -- (SBWIRE) -- 01/15/2018 -- General anxiety disorder (GAD) is characterized by constant and excessive worrying which is hard to control and lead to considerable impairment or distress. Other psychological symptoms of anxiety include irritability and apprehensiveness, and physical symptoms of anxiety are increased muscular tension and fatigue. Effective treatments for general anxiety disorder are medications and psychotherapy. Psychotherapy includes applied relaxation and cognitive-behavioral therapy among others.

Request Free Sample Research Report @ https://goo.gl/R1gFdq

According to anxiety and depression association of America, general anxiety disorder affects 3.1% of the U.S. population or 6.8 million adults, in any given year. U.S. stands for the major regional market for anxiety disorder therapeutics worldwide. Growing geriatric population and rising prevalence of anxiety disorders and depression are some of the key factors to drive the market in the years to come. Currently, U.S. general anxiety disorders market is saturated as a variety of antidepressant drugs are available on prescription for the similar symptom. Presently, general anxiety disorders market is on a decline owing to the weak pipeline of novel drugs, patent expiry of major antidepressants and an increasing number of cheap generic drug variants in the market.

Inquiry more about this report @ https://goo.gl/pcz6z2

Different therapeutic segments of the general anxiety disorder market include antidepressant, benzodiazepines and other therapeutics. The antidepressant was a major therapeutic segment of general anxiety disorder market and constituted 38.6% share of the total demand in 2014 and is expected to continue its dominance in the market over the forecast period. Numerous kinds of medications employed to treat general anxiety disorder. Antidepressants such as serotonin norepinephrine reuptake inhibitor (SNRI) and selective serotonin reuptake inhibitor (SSRI) classes are the first-line medication treatments. Benzodiazepines (clonazepam, alprazolam, diazepam, and lorazepam) are highly efficient in reducing muscular tension, promoting relaxation and other physical symptoms of anxiety.

Browse detail report with in-depth TOC @ https://goo.gl/kFKnQi

General anxiety market is highly competitive in nature owing to the presence of both large and small pharmaceutical companies. Eli Lilly and Company, Sanofi S.A. Forest Laboratories, Inc., Johnson & Johnson H. Lundbeck A/S, Merck & Co., Inc., Pfizer, Inc. are some of the dominant players in the market space.